Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG and DxS sign exclusive licence with AstraZeneca to commercialise ARMS DNA diagnostic technology

BTG : 28 September, 2006  (Technical Article)
DxS and BTG announced today that they have signed an exclusive licence with AstraZeneca to commercialise the company
DxS and BTG announced today that they have signed an exclusive licence with AstraZeneca to commercialise the company’s proprietary Amplification Refractory Mutation System DNA diagnostic technology. ARMS is a simple, reliable and widely used method for the detection of gene mutations and single nucleotide polymorphisms.

Under this agreement, BTG and DxS will assume certain rights to the intellectual property and will further commercialise the technology within the diagnostic and research markets. The licensing campaign will be aimed at maximising the commercial value for the ARMS technology via companies that offer products and services which relate to the detection of genetic variation, companies that are currently using ARMS technology as part of their in-house research activities, as well as encouraging new and novel applications for this powerful technology.

The $1 billion nucleic acid diagnostic market includes testing for infectious and genetic diseases, as well as cell/tissue typing, cancer genetics and personalised medicine. It is the fastest growing sector of the diagnostic marketplace, increasing at a rate of 20-40% per annum. This could, according to some industry experts, create a potential $8-10 billion market segment by 2010. ARMS technology has applications throughout this market such as the detection of genetic variations in the genes responsible for common diseases, including cancer and heart disease. ARMS can also be used in personalised medicine tests, to predict which individuals will respond well to a medicine, and typing infectious pathogens.

Dr Joe Carey, Vice President of BTG’s Strategic Business Development Group, commented, “We are pleased that AstraZeneca has elected to partner with BTG and DxS to realise the full value of its ARMS technology. BTG’s success in strategic licensing has been based upon gaining a thorough understanding of the technology and key market applications across a range of industries including the bio-medical field.”

Dr Stephen Little, CEO of DxS, added, “ARMS is an important and valuable genetic analysis technique. By combining the scientific and marketing expertise of DxS with the commercial capabilities of BTG, we will be able to release the inherent value of the AstraZeneca technology. DxS has considerable expertise in the development and application of technologies for nucleic acid analysis, and ARMS is an excellent fit with our current portfolio. We are looking forward to building on our long-standing relationship with AstraZeneca.”
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo